Wave Life Sciences plans single two-year registrational trial of WVE-006 in alpha-1 antitrypsin deficiency after FDA feedback

By Public Technologies
  • Wave Life Sciences outlined an FDA-aligned plan for a single two-year registrational trial of WVE-006 in alpha-1 antitrypsin deficiency.
  • The study design includes a one-year interim analysis that could support an accelerated approval filing based on biomarker evidence.
  • Results from the ongoing Phase 1b/2a RestorAATion-2 trial have not been presented; 600 mg monthly multidose data are due in Q4 2026.
  • Management described WVE-006 as generally safe and well tolerated to date, with no liver toxicities reported.
  • The FDA feedback removes the need for a separate confirmatory trial, potentially shortening timelines and lowering development risk for WVE-006.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010730PRIMZONEFULLFEED9837604) on October 01, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.